Grid is committed to advancing our unique strategy to develop better and safer medicines for our patients. This has and will continue to be our sole mission.

Our Phase Ib expansion cohort for patients with NSCLC is currently enrolling. Our Phase 2 GT103 combination trial with Pembrolizumab will begin enrollment at multiple sites in Q4 2022.

The trial is registered on the Clinical website.

For further support or questions contact:

Grid Therapeutics
Dr. Edward Patz,

Duke Thoracic Oncology
Phone number (919) 681-4768